These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 21944346)

  • 1. Young women with locally advanced breast cancer who achieve breast conservation after neoadjuvant chemotherapy have a low local recurrence rate.
    Sweeting RS; Klauber-Demore N; Meyers MO; Deal AM; Burrows EM; Drobish AA; Anders CK; Carey LA
    Am Surg; 2011 Jul; 77(7):850-5. PubMed ID: 21944346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loco-regional control after neo-adjuvant chemotherapy and conservative treatment for locally advanced breast cancer patients.
    Levy A; Borget I; Bahri M; Arnedos M; Rivin E; Vielh P; Balleyguier C; Rimareix F; Bourgier C
    Breast J; 2014; 20(4):381-7. PubMed ID: 24890310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy.
    Caudle AS; Yu TK; Tucker SL; Bedrosian I; Litton JK; Gonzalez-Angulo AM; Hoffman K; Meric-Bernstam F; Hunt KK; Buchholz TA; Mittendorf EA
    Breast Cancer Res; 2012 May; 14(3):R83. PubMed ID: 22621334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of risk of local-regional recurrence after mastectomy or breast conservation therapy for patients treated with neoadjuvant chemotherapy and radiation stratified according to a prognostic index score.
    Huang EH; Strom EA; Perkins GH; Oh JL; Chen AM; Meric-Bernstam F; Hunt KK; Sahin AA; Hortobagyi GN; Buchholz TA
    Int J Radiat Oncol Biol Phys; 2006 Oct; 66(2):352-7. PubMed ID: 16887286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of chemotherapy sequencing on local-regional failure risk in breast cancer patients undergoing breast-conserving therapy.
    Mittendorf EA; Buchholz TA; Tucker SL; Meric-Bernstam F; Kuerer HM; Gonzalez-Angulo AM; Bedrosian I; Babiera GV; Hoffman K; Yi M; Ross MI; Hortobagyi GN; Hunt KK
    Ann Surg; 2013 Feb; 257(2):173-9. PubMed ID: 23291658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Locoregional Control According to Breast Cancer Subtype and Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Undergoing Breast-conserving Therapy.
    Swisher SK; Vila J; Tucker SL; Bedrosian I; Shaitelman SF; Litton JK; Smith BD; Caudle AS; Kuerer HM; Mittendorf EA
    Ann Surg Oncol; 2016 Mar; 23(3):749-56. PubMed ID: 26511263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the MD Anderson Prognostic Index for local-regional recurrence after breast conserving therapy in patients receiving neoadjuvant chemotherapy.
    Akay CL; Meric-Bernstam F; Hunt KK; Grubbs EG; Bedrosian I; Tucker SL; Kuerer HM; Hoffman KE; Babiera GV; Strom EA; Buchholz TA; Mittendorf EA
    Ann Surg Oncol; 2012 Mar; 19(3):901-7. PubMed ID: 21861223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast-conserving therapy after neoadjuvant chemotherapy: long-term results.
    Beriwal S; Schwartz GF; Komarnicky L; Garcia-Young JA
    Breast J; 2006; 12(2):159-64. PubMed ID: 16509842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of breast cancer molecular subtypes on locoregional recurrence in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer.
    Meyers MO; Klauber-Demore N; Ollila DW; Amos KD; Moore DT; Drobish AA; Burrows EM; Dees EC; Carey LA
    Ann Surg Oncol; 2011 Oct; 18(10):2851-7. PubMed ID: 21442348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy.
    Huang EH; Tucker SL; Strom EA; McNeese MD; Kuerer HM; Hortobagyi GN; Buzdar AU; Valero V; Perkins GH; Schechter NR; Hunt KK; Sahin AA; Buchholz TA
    Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):351-7. PubMed ID: 15890574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors affecting locoregional recurrence in breast cancer patients undergoing surgery following neoadjuvant treatment.
    Chou HH; Chung WS; Ding RY; Kuo WL; Yu CC; Tsai HP; Shen SC; Chu CH; Lo YF; Chen SC
    BMC Surg; 2021 Mar; 21(1):160. PubMed ID: 33757489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combining Clinical and Pathologic Staging Variables Has Prognostic Value in Predicting Local-regional Recurrence Following Neoadjuvant Chemotherapy for Breast Cancer.
    Vila J; Teshome M; Tucker SL; Woodward WA; Chavez-MacGregor M; Hunt KK; Mittendorf EA
    Ann Surg; 2017 Mar; 265(3):574-580. PubMed ID: 27735826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Locoregional Recurrence by Tumor Biology in Breast Cancer Patients after Preoperative Chemotherapy and Breast Conservation Treatment.
    Jwa E; Shin KH; Kim JY; Park YH; Jung SY; Lee ES; Park IH; Lee KS; Ro J; Kim YJ; Kim TH
    Cancer Res Treat; 2016 Oct; 48(4):1363-1372. PubMed ID: 26910473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term outcome of neoadjuvant therapy for locally advanced breast carcinoma: effective clinical downstaging allows breast preservation and predicts outstanding local control and survival.
    Cance WG; Carey LA; Calvo BF; Sartor C; Sawyer L; Moore DT; Rosenman J; Ollila DW; Graham M
    Ann Surg; 2002 Sep; 236(3):295-302; discussion 302-3. PubMed ID: 12192316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast-conservation therapy for lymph node-negative, human epidermal growth factor receptor 2-positive breast cancer.
    Kiess AP; McArthur HL; Mahoney K; Patil S; Morris PG; Ho A; Hudis CA; McCormick B
    Cancer; 2012 Apr; 118(8):1982-8. PubMed ID: 21887681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes and predictive factors for salvage therapy after local--regional recurrence following neoadjuvant chemotherapy and breast conserving therapy.
    Weksberg DC; Allen PK; Hoffman KE; Litton JK; Strom EA; Shah RR; Kuerer HM; Hunt KK; Buchholz TA; Mittendorf EA
    Ann Surg Oncol; 2013 Oct; 20(11):3430-7. PubMed ID: 23720073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can we predict local recurrence in breast conserving surgery after neoadjuvant chemotherapy?
    Cebrecos I; Córdoba O; Deu J; Xercavins J; Rubio IT
    Eur J Surg Oncol; 2010 Jun; 36(6):528-34. PubMed ID: 20444571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Indications for Postmastectomy Radiation After Neoadjuvant Chemotherapy in ypN0 and ypN1-3 Axillary Node-Positive Women.
    Fowble B; Jairam AK; Wang F; Peled A; Alvarado M; Ewing C; Esserman L; Park C; Lazar A
    Clin Breast Cancer; 2018 Feb; 18(1):e107-e113. PubMed ID: 28830795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triple-negative breast cancer is not a contraindication for breast conservation.
    Adkins FC; Gonzalez-Angulo AM; Lei X; Hernandez-Aya LF; Mittendorf EA; Litton JK; Wagner J; Hunt KK; Woodward WA; Meric-Bernstam F
    Ann Surg Oncol; 2011 Oct; 18(11):3164-73. PubMed ID: 21947595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T3 disease at presentation or pathologic involvement of four or more lymph nodes predict for locoregional recurrence in stage II breast cancer treated with neoadjuvant chemotherapy and mastectomy without radiotherapy.
    Garg AK; Strom EA; McNeese MD; Buzdar AU; Hortobagyi GN; Kuerer HM; Perkins GH; Singletary SE; Hunt KK; Sahin A; Schechter N; Valero V; Tucker SL; Buchholz TA
    Int J Radiat Oncol Biol Phys; 2004 May; 59(1):138-45. PubMed ID: 15093909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.